Preliminary Report - ID Mapping
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision Next revision Both sides next revision | ||
|
covid:unpublished [2020/08/05 13:15] biogridadmin |
covid:unpublished [2020/08/27 20:23] biogridadmin |
||
|---|---|---|---|
| Line 9: | Line 9: | ||
| | **888800000002** | **[[https://doi.org/10.1101/2020.03.29.20041962|10.1101/2020.03.29.20041962]]** | Gao T (2020) | **[[https://thebiogrid.org/221112/publication|Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation]]** | | | **888800000002** | **[[https://doi.org/10.1101/2020.03.29.20041962|10.1101/2020.03.29.20041962]]** | Gao T (2020) | **[[https://thebiogrid.org/221112/publication|Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation]]** | | ||
| | **888800000003** | **[[https://doi.org/10.1101/2020.02.16.951723|10.1101/2020.02.16.951723]]** | Sun C (2020) | **[[https://thebiogrid.org/221178/publication|SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development]]** | | | **888800000003** | **[[https://doi.org/10.1101/2020.02.16.951723|10.1101/2020.02.16.951723]]** | Sun C (2020) | **[[https://thebiogrid.org/221178/publication|SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development]]** | | ||
| - | | **888800000004** | **[[https://doi.org/10.1101/2020.03.16.994236|10.1101/2020.03.16.994236]]** | Procko E (2020) | **[[https://thebiogrid.org/221182/publication|The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2]]** | | ||
| | **888800000005** | **[[https://doi.org/10.1101/2020.03.14.988345|10.1101/2020.03.14.988345]]** | Wang K (2020) | **[[https://thebiogrid.org/221183/publication|SARS-CoV-2 invades host cells via a novel route: CD147-spike protein]]** | | | **888800000005** | **[[https://doi.org/10.1101/2020.03.14.988345|10.1101/2020.03.14.988345]]** | Wang K (2020) | **[[https://thebiogrid.org/221183/publication|SARS-CoV-2 invades host cells via a novel route: CD147-spike protein]]** | | ||
| | **888800000006** | **[[https://doi.org/10.1101/2020.02.17.951848|10.1101/2020.02.17.951848]]** | Zhou Q (2020) | **[[https://thebiogrid.org/221185/publication|Structure of dimeric full-length human ACE2 in complex with B0AT1]]** | | | **888800000006** | **[[https://doi.org/10.1101/2020.02.17.951848|10.1101/2020.02.17.951848]]** | Zhou Q (2020) | **[[https://thebiogrid.org/221185/publication|Structure of dimeric full-length human ACE2 in complex with B0AT1]]** | | ||
| Line 50: | Line 49: | ||
| | **888800000045** | **[[https://doi.org/10.1101/2020.06.05.134114|10.1101/2020.06.05.134114]]** | Daly JL (2020) | **[[https://thebiogrid.org/222653/publication|Neuropilin-1 is a host factor for SARS-CoV-2 infection]]** | | | **888800000045** | **[[https://doi.org/10.1101/2020.06.05.134114|10.1101/2020.06.05.134114]]** | Daly JL (2020) | **[[https://thebiogrid.org/222653/publication|Neuropilin-1 is a host factor for SARS-CoV-2 infection]]** | | ||
| | **888800000046** | **[[https://doi.org/10.1101/2020.06.17.158121|10.1101/2020.06.17.158121]]** | Cubuk J (2020) | **[[https://thebiogrid.org/222654/publication|The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA]]** | | | **888800000046** | **[[https://doi.org/10.1101/2020.06.17.158121|10.1101/2020.06.17.158121]]** | Cubuk J (2020) | **[[https://thebiogrid.org/222654/publication|The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA]]** | | ||
| - | | **888800000047** | **[[https://doi.org/10.1101/2020.06.09.142794|10.1101/2020.06.09.142794]]** | Yang Y (2020) | **[[https://thebiogrid.org/222655/publication|The utility of native MS for understanding the mechanism of action of repurposed therapeutics in COVID-19: heparin as a disruptor of the SARS-CoV-2 interaction with its host cell receptor.]]** | | ||
| | **888800000048** | **[[https://doi.org/10.1101/2020.06.02.130161|10.1101/2020.06.02.130161]]** | Hanke L (2020) | **[[https://thebiogrid.org/222656/publication|An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction]]** | | | **888800000048** | **[[https://doi.org/10.1101/2020.06.02.130161|10.1101/2020.06.02.130161]]** | Hanke L (2020) | **[[https://thebiogrid.org/222656/publication|An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction]]** | | ||
| | **888800000049** | **[[https://doi.org/10.1101/2020.06.17.156471|10.1101/2020.06.17.156471]]** | Conceicao C (2020) | **[[https://thebiogrid.org/222704/publication|The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins]]** | | | **888800000049** | **[[https://doi.org/10.1101/2020.06.17.156471|10.1101/2020.06.17.156471]]** | Conceicao C (2020) | **[[https://thebiogrid.org/222704/publication|The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins]]** | | ||